Reviewing Stevanato Group (NYSE:STVN) and Heatwurx (NASDAQ:PCSA)

Heatwurx (NASDAQ:PCSA) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Heatwurx and Stevanato Group, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1	1	1	0	2.00
Stevanato Group	1	1	3	0	2.40

Heatwurx currently has a consensus target price of $25.00, indicating a potential upside of 738.93%. Given Heatwurx’s higher probable upside, analysts plainly believe Heatwurx is more favorable than Stevanato Group.

Institutional & Insider Ownership

91.9% of Heatwurx shares are held by institutional investors. 2.4% of Heatwurx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Heatwurx and Stevanato Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-257.81%	-191.10%
Stevanato Group	11.83%	10.44%	6.22%

Volatility & Risk

Heatwurx has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.

Valuation and Earnings

This table compares Heatwurx and Stevanato Group”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56 million	($34.00)	-0.09
Stevanato Group	$1.34 billion	3.66	$158.21 million	€0.58	27.96

Stevanato Group has higher revenue and earnings than Heatwurx. Heatwurx is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Summary

Stevanato Group beats Heatwurx on 9 of the 13 factors compared between the two stocks.

About Heatwurx

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.